Influence of MUC1 genetic variation on prostate cancer risk and survival

European Journal of Human Genetics

Volumn 16, Issue 12, 2008, Pages 1521-1525

  Strawbridge, Rona J ^a   Nister, Monica ^a   Brismar, Kerstin ^a   Li, Chunde ^a   Lindström, Sara ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; INHERITANCE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MUCIN-1; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; SWEDEN;

EID: 56749184908     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.131     Document Type: Article

References (25)

1. Lapointe J, Li C, Higgins JP et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
2. Arai T, Fujita K, Fujime M, Irimura T: Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int J Urol 2005; 12: 654-661.
3. Cozzi PJ, Wang J, Delprado W et al: MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22: 565-573.
4. Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-353.
5. Stepensky D, Tzehoval E, Vadai E, Eisenbach L: O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006; 143: 139-149.
6. Wesseling J, van der Valk SW, Hilkens J: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-577.
7. Ligtenberg MJ, Gennissen AM, Vos HL, Hilkens J: A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res 1991; 19: 297-301.
8. Fowler JC, Teixeira AS, Vinall LE, Swallow DM: Hypervariability of the membrane-associated mucin and cancer marker MUC1. Hum Genet 2003; 113: 473-479.
9. Obermair A, Schmid BC, Packer LM et al: Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 2002; 100: 166-171.
10. Carvalho F, Seruca R, David L et al: MUC1 gene polymorphism and gastric cancer an epidemiological study. Glycoconj J 1997; 14 107-111.
11. Schmid BC, Buluwela L, Liu Q et al: Expression of MUCI splice variants correlates with invasive growth of breast cancer cell lines. Breast Cancer Res Treat 2002; 76: 211-219.
12. Zheng SL, Sun J, Wiklund F et al: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358 910-919.
13. Lindstrom S, Adami HO, Balter KA et al: Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007; 13: 5156-5161.
14. Frazer KA, Ballinger DG, Cox DR et al: A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
15. Gabriel SB, Schaffner SF, Nguyen H et al: The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
16. Stram DO, Haiman CA, Hirschhorn JN et al: Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003; 55: 27-36.
17. BarreAt JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
18. Lindstrom S, Wiklund F, Adami HO, Balter KA, Adolfsson J, Gronberg H: Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res 2006; 66: 11077-11083.
19. Jurinke C, van den Boom D, Cantor CR, Koster H: Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2001; 170 103-116.
20. http://lib.stat.cmu.edu/R/CRAN/index.html.
21. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
22. Tregouet DA, Tiret L: Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm. Eur J Hum Genet 2004; 12: 971-974.
23. Parry S, Hanisch FG, Leir SH et al: N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology 2006; 16 623-634.
24. Andren O, Fall K, Andersson SO et al: MUC-1 gene is associated with prostate cancer death: A 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007; 97: 730-734.
25. Strawbridge RJ, Nistér M, Brismar K, Grönberg H, Li C: MUC1 as a putative prognostic marker for prostate cancer. Biomarker Insights 2008; 3: 303-315.